8-K: Orgenesis Inc. to Acquire Full Ownership of Octomera LLC in Strategic Move

Orgenesis Inc. has entered into a binding term sheet to acquire all remaining equity interests of its subsidiary Octomera LLC from MM OS Holdings L.P.

Summary

• Orgenesis Inc. has agreed to acquire the remaining 3,670,324 Class A Preferred Units of Octomera LLC from MM OS Holdings L.P., an affiliate of Metalmark Capital Partners.
• The acquisition will give Orgenesis full ownership of Octomera.
• The consideration includes the termination of an advisory agreement, the restructuring of outstanding loans, a 5% royalty on Octomera's net revenue for four years, and a potential milestone payment.
• The royalty can be bought out by Orgenesis for $40 million in cash and/or equity.
• A milestone payment of 5% of net proceeds will be paid to the seller if Octomera is sold for more than $40 million within five years, or if there is a change of control of Orgenesis with a similar valuation.
• The seller will settle all outstanding ownership claims of Octomera, ensuring Orgenesis owns all equity interests at closing.
• The seller's board members will resign, and Octomera will become a single-member LLC.
• Orgenesis will pay up to $300,000 of the seller's legal expenses within 90 days of closing.

Sentiment

Score: 7

Explanation: The acquisition is a positive step for Orgenesis, consolidating its ownership of Octomera. The terms of the deal are reasonable, with some potential future costs. Overall, the sentiment is positive but not overly enthusiastic.

Positives

• Orgenesis will gain full control of Octomera LLC, simplifying its corporate structure.
• The termination of the advisory agreement with Metalmark Management II LLC will remove ongoing costs.
• The restructuring of loans provides Orgenesis with a longer repayment period of 10 years.
• The buyout option for the royalty stream provides flexibility for Orgenesis.
• The settlement of all outstanding ownership claims ensures a clean ownership structure for Octomera.

Negatives

• Orgenesis will be obligated to pay a 5% royalty on Octomera's net revenue for four years.
• A potential milestone payment of 5% of net proceeds is required if Octomera is sold for more than $40 million within five years.
• Orgenesis will need to pay up to $300,000 of the seller's legal expenses.

Risks

• The acquisition is subject to the execution of definitive agreements.
• The milestone payment is contingent on future events, such as a sale of Octomera or a change of control of Orgenesis.
• The royalty payments could impact Orgenesis's profitability for the next four years.
• The successful integration of Octomera's operations into Orgenesis is crucial for the deal's success.

Future Outlook

The company will negotiate definitive agreements to complete the acquisition of Octomera. The company will also need to integrate Octomera's operations and manage the royalty and potential milestone payments.

Industry Context

This acquisition is a strategic move by Orgenesis to consolidate its ownership of Octomera, potentially streamlining operations and future growth. This type of acquisition is common in the biotech industry as companies look to consolidate assets and control their subsidiaries.

Comparison to Industry Standards

• The acquisition structure, including royalty payments and milestone payments, is a common practice in the biotech industry.
• The 5% royalty is within the typical range for similar deals, although the specific terms will depend on the financial performance of Octomera.
• The $40 million buyout option provides Orgenesis with flexibility, which is a common feature in such agreements.
• The milestone payment structure is also typical, incentivizing the seller while protecting the buyer from overpaying upfront.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will likely view the acquisition positively as it consolidates ownership and potentially streamlines operations.
• Employees of Octomera will likely see no immediate changes, but the long-term impact will depend on the integration process.
• Customers and suppliers of Octomera are unlikely to be significantly impacted by the acquisition.

Next Steps

• Negotiate and execute definitive agreements for the acquisition.
• Complete the closing of the acquisition.
• Integrate Octomera's operations into Orgenesis.
• Manage royalty payments and potential milestone payments.

Key Dates

Keywords

acquisition, Orgenesis, Octomera, equity, royalty, milestone, Metalmark Capital, term sheet